Related Experiment Video
Updated: Dec 6, 2025
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
441
THE ROLE OF NT PRO-BNP IN THE EVALUATION OF DIABETIC PATIENTS WITH HEART FAILURE
F I Fringu1, A V Sitar-Taut2, B Caloian3
1University of Medicine and Pharmacy, Clinical Rehabilitation Hospital, Cardiology Department, Cluj-Napoca, Romania.
Acta Endocrinologica (Bucharest, Romania : 2005)
|October 8, 2020
Summary
NT-pro-BNP levels are crucial for evaluating diabetic patients with heart failure (HF). These levels correlate with key health indicators and aid in management, especially in patients with diabetes mellitus (DM).
Area of Science:
- Cardiology
- Endocrinology
- Biomarkers
Background:
- The co-occurrence of heart failure (HF) and diabetes mellitus (DM) presents a significant clinical challenge due to high prevalence.
- Effective management strategies for these patients require accurate assessment tools.
Purpose of the Study:
- To investigate the diagnostic and prognostic role of NT-pro-BNP levels in patients with both diabetes and heart failure.
- To identify specific clinical parameters that correlate with NT-pro-BNP levels in this patient cohort.
Main Methods:
- A retrospective cohort study involving 174 patients diagnosed with HF.
- Patients were assessed for the presence of DM, with 47.7% having concomitant diabetes.
- NT-pro-BNP levels were measured, with a threshold of 126 pg/mL indicating a high probability of HF.
Main Results:
- In diabetic HF patients, NT-pro-BNP levels showed significant correlations with hemoglobin, hematocrit, total cholesterol, triglycerides, ejection fraction, end-diastolic volume, and end-systolic volume.
- Independent predictors of elevated NT-pro-BNP included ejection fraction, hemoglobin, and triglycerides.
- These findings highlight specific biomarkers associated with NT-pro-BNP in diabetic HF.
Conclusions:
- NT-pro-BNP is a pivotal biomarker for evaluating the status of diabetic patients with heart failure.
- Utilizing NT-pro-BNP facilitates appropriate management and follow-up strategies for this complex patient group.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
396
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
396
01:30Heart Failure VII: Nursing Interventions
294
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
294
01:22Heart Failure Drugs: β-Blockers
610
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
610
01:29Heart Failure II: Pathophysiology
502
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
502
01:30Heart Failure IV: Classification and Diagnostic Evaluation
183
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
183
01:30Heart Failure V: Medical Management
122
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
122